兴科蓉医药(06833.HK)与北京北大未名生物工程达成战略合作
格隆汇9月20日丨兴科蓉医药(06833.HK)发布公告,2019年9月20日,公司与北京北大未名生物工程集团有限公司就订约方于生物医药、疫苗、医疗设备及医疗保健服务领域上的合作订立无法律约束力的战略合作协议。
根据合作协议,订约方将在资本及业务方面于生物医药、疫苗、医疗设备及医疗保健服务领域上合作。此外,订约方将共同研究具体合作模式,并安排实施订约方的建议合作。根据合作协议,于落实建议合作后,公司将利用其市场资源及销售渠道协助北京北大未名生物工程推广北京北大未名生物工程的产品。
北京北大未名生物工程于1992年成立,为北京大学持有的产业集团之一。北京北大未名生物工程主要从事建立生物经济体系及发展生物经济业务,并专注于七个重要领域,即生物医学、生物农业、生物能源、生物环保、生物服务、生物制造及生物智能。
公司订立合作协议旨在与北京北大未名生物工程制定合作计划,利用订约方各自的优势、资源及专业知识,从而提升集团的竞争力。订立合作协议与集团的业务策略一致,以发掘生物医学行业的业务及╱或投资机会。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.